EHA 2019 | Nelarabine for R/R T-cell ALL

Robin Foà

Robin Foà, MD, Sapienza University of Rome, Rome, Italy, discusses a phase IIII study investigating nelarabine as salvage and bridging therapy to allogeneic stem-cell transplantation in adult patients with relapsed/refractory t-cell acute lymphoblastic leukemia(ALL). This interview was held at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

Share this video  
Similar topics